-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Cryo-Cell International, Inc. (OTCMKTS:CCEL) CEO Buys $18,865.00 in Stock
Cryo-Cell International, Inc. (OTCMKTS:CCEL) CEO Buys $18,865.00 in Stock
Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) CEO David Portnoy purchased 3,850 shares of Cryo-Cell International stock in a transaction dated Thursday, November 10th. The stock was acquired at an average price of $4.90 per share, for a total transaction of $18,865.00. Following the completion of the transaction, the chief executive officer now owns 117,012 shares in the company, valued at approximately $573,358.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
David Portnoy also recently made the following trade(s):
Get Cryo-Cell International alerts:- On Tuesday, November 8th, David Portnoy purchased 20,000 shares of Cryo-Cell International stock. The stock was acquired at an average price of $4.89 per share, for a total transaction of $97,800.00.
Cryo-Cell International Trading Down 3.6 %
Cryo-Cell International stock opened at $4.77 on Friday. The stock has a market cap of $40.64 million, a price-to-earnings ratio of 33.00 and a beta of 0.35. The company's 50-day moving average price is $5.83 and its two-hundred day moving average price is $5.96. Cryo-Cell International, Inc. has a 52 week low of $4.68 and a 52 week high of $14.00.
Cryo-Cell International (OTCMKTS:CCEL – Get Rating) last released its earnings results on Friday, October 14th. The company reported $0.06 EPS for the quarter. The firm had revenue of $7.70 million for the quarter. Cryo-Cell International had a net margin of 4.34% and a return on equity of 49.62%.Cryo-Cell International Dividend Announcement
The business also recently announced a dividend, which was paid on Friday, September 9th. Shareholders of record on Friday, September 2nd were paid a dividend of $0.90 per share. The ex-dividend date was Thursday, September 1st.
Wall Street Analysts Forecast Growth
Separately, Maxim Group began coverage on shares of Cryo-Cell International in a research report on Monday, August 29th. They issued a "buy" rating and a $12.00 price objective on the stock.
Hedge Funds Weigh In On Cryo-Cell International
A hedge fund recently raised its stake in Cryo-Cell International stock. Massmutual Trust Co. FSB ADV lifted its holdings in Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) by 63.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 124,135 shares of the company's stock after purchasing an additional 48,100 shares during the period. Massmutual Trust Co. FSB ADV owned about 1.47% of Cryo-Cell International worth $732,000 at the end of the most recent reporting period. Institutional investors own 9.01% of the company's stock.
About Cryo-Cell International
(Get Rating)
Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.
Recommended Stories
- Get a free copy of the StockNews.com research report on Cryo-Cell International (CCEL)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.
Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) CEO David Portnoy purchased 3,850 shares of Cryo-Cell International stock in a transaction dated Thursday, November 10th. The stock was acquired at an average price of $4.90 per share, for a total transaction of $18,865.00. Following the completion of the transaction, the chief executive officer now owns 117,012 shares in the company, valued at approximately $573,358.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
冷凍細胞國際公司首席執行官David·波特諾伊在11月10日星期四的交易中購買了3,850股冷凍細胞國際公司的股票。股票是以每股4.90美元的平均價格收購的,總交易額為18865.00美元。交易完成後,首席執行官現在擁有該公司117,012股,價值約573,358.80美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以通過美國證券交易委員會網站.
David Portnoy also recently made the following trade(s):
David·波特諾伊最近還進行了以下交易:
- On Tuesday, November 8th, David Portnoy purchased 20,000 shares of Cryo-Cell International stock. The stock was acquired at an average price of $4.89 per share, for a total transaction of $97,800.00.
- 11月8日,星期二,David·波特諾伊購買了20,000股冷凍細胞國際股票。這隻股票是以每股4.89美元的平均價格收購的,總交易額為97,800.00美元。
Cryo-Cell International Trading Down 3.6 %
低温細胞國際股價下跌3.6%
Cryo-Cell International stock opened at $4.77 on Friday. The stock has a market cap of $40.64 million, a price-to-earnings ratio of 33.00 and a beta of 0.35. The company's 50-day moving average price is $5.83 and its two-hundred day moving average price is $5.96. Cryo-Cell International, Inc. has a 52 week low of $4.68 and a 52 week high of $14.00.
Cryo-Cell International的股票週五開盤報4.77美元。該股市值為4,064萬美元,市盈率為33.00倍,貝塔係數為0.35。該公司的50日移動均線價格為5.83美元,200日移動均線價格為5.96美元。Cryo-Cell International,Inc.的52周低點為4.68美元,52周高位為14.00美元。
Cryo-Cell International Dividend Announcement
低温細胞國際分紅公告
The business also recently announced a dividend, which was paid on Friday, September 9th. Shareholders of record on Friday, September 2nd were paid a dividend of $0.90 per share. The ex-dividend date was Thursday, September 1st.
該公司最近還宣佈了股息,股息於9月9日(星期五)支付。9月2日星期五登記在冊的股東獲得了每股0.90美元的股息。除息日期為9月1日星期四。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Separately, Maxim Group began coverage on shares of Cryo-Cell International in a research report on Monday, August 29th. They issued a "buy" rating and a $12.00 price objective on the stock.
另外,Maxim Group在8月29日星期一的一份研究報告中開始報道Cryo-Cell International的股票。他們對該股的評級為“買入”,目標價為12美元。
Hedge Funds Weigh In On Cryo-Cell International
對衝基金看好Cryo-Cell International
A hedge fund recently raised its stake in Cryo-Cell International stock. Massmutual Trust Co. FSB ADV lifted its holdings in Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) by 63.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 124,135 shares of the company's stock after purchasing an additional 48,100 shares during the period. Massmutual Trust Co. FSB ADV owned about 1.47% of Cryo-Cell International worth $732,000 at the end of the most recent reporting period. Institutional investors own 9.01% of the company's stock.
一家對衝基金最近增持了Cryo-Cell International股票。麻省互惠信託股份有限公司(MassMutual Trust Co.FSB ADV)最近提交給美國證券交易委員會(Securities and Exchange Commission,簡稱:美國證券交易委員會)的文件顯示,該公司在第二季度增持了Cryo-Cell International,Inc.的股份63.3%。該基金在此期間額外購買了48,100股後,擁有124,135股該公司的股票。截至最近一次報告期結束時,MassMutual Trust Co.FSB ADV擁有Cryo-Cell International約1.47%的股份,價值73.2萬美元。機構投資者持有該公司9.01%的股票。
About Cryo-Cell International
關於冷凍細胞國際公司
(Get Rating)
(獲取評級)
Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.
國際冷凍細胞公司從事細胞處理和低温細胞存儲,專注於收集和保存供家庭使用的臍帶血幹細胞。它提供臍帶組織服務,存儲部分臍帶組織,臍帶組織是間充質幹細胞的來源,用於再生醫學,用於治療一系列疾病,包括心臟、腎臟疾病、肌萎縮側索硬化症、傷口癒合和自身免疫性疾病。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Cryo-Cell International (CCEL)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- 免費獲取StockNews.com關於低温細胞國際(CCEL)的研究報告
- MarketBeat:回顧中的一週11/7-11/11
- 油價是股市拋售尚未結束的一個令人信服的原因
- 中盤Neurocrine生物科學是井噴後的第三季度報告嗎?
- 六面旗幟是一種你不想被困住的旅程
- Hanesbrand可能發出零售類股本週表現不佳的信號
Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.
接受《冷凍細胞國際日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cryo-Cell International和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧